Addiction (Addiction )
Addiction was established in 1884 and has been in continuous publication ever since the longest established journal in its field. It has built up a reputation in that time for scientific quality for the diversity of material it publishes and for its pioneering role in stimulating and leading debate. It is committed to promoting communication - between disciplines between cultures and between scientists practitioners and policy-makers. Addiction has been successful in these goals because of the huge cast of top specialists throughout the world who contribute to its work through their rigorous peer reviewing writing advice and support in many other ways. We have strengthened commitment to internationalism and to our authors by recently establishing regional offices for the Americas and for Australasia to speed the handling of papers and bring authors and editors closer. Addiction also receives wide media coverage internationally.
Current impact factor: 4.60
Impact Factor Rankings
|2015 Impact Factor||Available summer 2015|
|2013/2014 Impact Factor||4.596|
|2012 Impact Factor||4.577|
|2011 Impact Factor||4.313|
|2010 Impact Factor||4.145|
|2009 Impact Factor||3.842|
|2008 Impact Factor||4.244|
Impact factor over time
|Other titles||Addiction (Abingdon, England: Online)|
|Material type||Document, Periodical, Internet resource|
|Document type||Internet Resource, Computer File, Journal / Magazine / Newspaper|
- Author can archive a pre-print version
- Author cannot archive a post-print version
- Some journals impose embargoes typically of 6 or 12 months, occasionally of 24 months
- no listing of affected journals available as yet
- See Wiley-Blackwell entry for articles after February 2007
- Publisher's version/PDF cannot be used
- On author's server, institutional server or subject-based server
- Server must be non-commercial
- Publisher copyright and source must be acknowledged with set statement ("The definitive version is available at www.blackwell-synergy.com")
- Articles in some journals can be made Open Access on payment of additional charge
- 'Blackwell Publishing' is an imprint of 'Wiley'
- Classification yellow
Publications in this journal
- Addiction 03/2015; 110(3):378-80.
- Addiction 03/2015; 110(3):390-1.
- Addiction 03/2015; 110(3):414-5.
- Addiction 03/2015; 110(3):388-9.
- Addiction 03/2015; 110(3):375-7.
Article: Where is the forest?Addiction 03/2015; 110(3):416-7.
- Addiction 03/2015; 110(3):511-2.
- Addiction 03/2015; 110(3):417-8.
- Addiction 03/2015; 110(3):387-8.
- Addiction 03/2015; 110(3):491-3.
- Addiction 03/2015; 110(3):389-90.
- [Show abstract] [Hide abstract]
ABSTRACT: Relapse to addiction following incarceration is common. We estimated the feasibility and effectiveness of extended-release naltrexone (XR-NTX) as relapse prevention among opioid dependent male adults leaving a large urban jail. 8-week, proof-of-concept, open-label, non-blinded randomized effectiveness trial. New York City jails and Bellevue Hospital Center Adult Primary Care clinics, USA PARTICIPANTS: From Jan 2010 to July 2013, 34 opioid dependent adult males with no interest in agonist treatments (methadone, buprenorphine) received a counseling and referral intervention and were randomized to XR-NTX (n = 17) vs. no medication (n = 17) within a week of jail release. XR-NTX(Vivitrol®; Alkermes Inc.), a long-acting injectable mu opioid receptor antagonist. The primary intent-to-treat outcome was post-release opioid relapse at week 4, defined as >10 days of opioid misuse by self-report and urine toxicologies. Secondary outcomes were proportion of urine samples negative for opioids and rates of opioid abstinence, intravenous drug use (IVDU), cocaine use, community treatment participation, re-incarceration, and overdose. Acceptance of XR-NTX was high; 15 of 17 initiated treatment. Rates of the primary outcome of week 4 opioid relapse were lower among XR-NTX participants: 38% vs. 88% (p < 0.004; Odds Ratio 0.08 [95% CI, 0.01-0.48]); more XR-NTX urine samples were negative for opioids, 59% vs. 24% (p < 0.009; OR 3.5 [95%CI, 1.4-8.5]). There were no significant differences in the remaining secondary outcomes, including rates of IVDU, cocaine use, re-incarceration, and overdose. Extended-release naltrexone is associated with significantly lower rates of opioid relapse among men in the USA following release from jail when compared with a no medication treatment-as-usual condition. This article is protected by copyright. All rights reserved.Addiction 02/2015;
- [Show abstract] [Hide abstract]
ABSTRACT: To evaluate biochemically verified smoking status, and electronic nicotine delivery systems (ENDS) use behaviors and beliefs among a sample of customers from vapor stores (stores specializing in ENDS). A cross-sectional survey of 215 adult vapor store customers at four retail locations in the Midwestern United States; a subset of participants (n=181) also completed exhaled carbon monoxide (CO) testing to verify smoking status. Outcomes evaluated included ENDS preferences, harm beliefs, use behaviors, smoking history and current biochemically verified smoking status. Most customers reported starting ENDS as a means of smoking cessation (86%), using newer generation devices (89%), vaping non-tobacco/non-menthol flavors (72%), and using e-liquid with nicotine strengths of ≤20 mg/ml (72%). There was a high rate of switching (91.4%) to newer generation ENDS among those who started with a first generation product. Exhaled CO readings confirmed that 66% of the tested sample had quit smoking. Among those who continued to smoke, mean cigarettes per day decreased from 22.1 to 7.5 (p <.001). People who reported vaping longer (OR=4.7, 95% CI = 2.0-10.8), using newer generation devices (OR=3.0, 95% CI = 1.0-8.4) and using non-tobacco and non-menthol flavors (OR=2.6, 95% CI = 1.1-6.1) were more likely to have quit smoking. Among vapor store customers in the US who use electronic nicotine delivery devices to stop smoking, vaping longer, using newer generation devices, and using non-tobacco and non-menthol flavored e-liquid appear to be associated with higher rates of smoking cessation. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.Addiction 02/2015;
- Addiction 02/2015;
- Addiction 02/2015; 110(2):205-6.
- Addiction 02/2015; 110(2):366-7.
- Addiction 02/2015; 110(2):193-4.
- Addiction 02/2015; 110(2):206-7.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.